1. Home
  2. TSAT vs LXEO Comparison

TSAT vs LXEO Comparison

Compare TSAT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telesat Corporation

TSAT

Telesat Corporation

HOLD

Current Price

$47.44

Market Cap

697.5M

Sector

Industrials

ML Signal

HOLD

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$3.18

Market Cap

348.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSAT
LXEO
Founded
1969
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
697.5M
348.7M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
TSAT
LXEO
Price
$47.44
$3.18
Analyst Decision
Hold
Strong Buy
Analyst Count
1
9
Target Price
★ $37.00
$18.44
AVG Volume (30 Days)
102.0K
★ 896.3K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 39.81
EPS
★ N/A
N/A
Revenue
N/A
★ $654,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.01
$3.27
52 Week High
$61.54
$10.99

Technical Indicators

Market Signals
Indicator
TSAT
LXEO
Relative Strength Index (RSI) 48.61 19.53
Support Level $41.65 N/A
Resistance Level $52.11 $5.38
Average True Range (ATR) 2.76 0.24
MACD -0.14 -0.12
Stochastic Oscillator 22.59 0.61

Price Performance

Historical Comparison
TSAT
LXEO

About TSAT Telesat Corporation

Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. The company has two operating segments: GEO services (GEO) segment that refers to the operation of the fleet of GEO satellite and LEO services (LEO) segment that refers to the deployment and operation of the Telesat Lightspeed constellation Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Share on Social Networks: